Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults
Authors:
- Peter L AndersonPAPeter L Anderson
- Jia-Hua ZhengJZJia-Hua Zheng
- Tracy KingTKTracy King
- Lane R BushmanLBLane R Bushman
- Julie PredhommeJPJulie Predhomme
- Amie MeditzAMAmie Meditz
- John GerberJGJohn Gerber
- Courtney V FletcherCFCourtney V Fletcher
- 1 September 2007
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (14) , 1849-1854
Abstract
Concentrations of zidovudine (ZDV)- and lamivudine (3TC)-triphosphates (TP) have been quantified in unfractionated peripheral blood mononuclear cells (PBMC) from HIV+ patients. The objective of this study was to determine whether concentrations of ZDV-TP and 3TC-TP in PBMC reflect the concentrations within CD4 T cells in HIV-seronegative adults. Volunteers had taken 300 mg of ZDV plus 150 mg of 3TC twice daily for ≥ 7 days. Blood (60 mL) was collected 2 or 5 h post observed dose. PBMC were processed into three cell fractions using CD4 magnetic immunobeads: CD4-purified cells; unfractionated PBMC; and CD4-depleted PBMC. TP were determined in each cell fraction with liquid chromatography–mass spectrometry and compared across cell types by non-parametric analyses. Six males and two females participated. The median (range) percentage of CD4 T cells (CD4%) in each fraction were: CD4-purified, 99%; unfractionated, 63% (range, 53–70); and CD4-depleted, 14% (range, 4–29). Corresponding median (range) ZDV-TP concentrations were 8.0 (5.3–10.3), 26.5 (12.9–42.2), and 34.2 (16.4–52.2) fmol/1 × 106 cells (Friedman P = 0.0008). The 3TC-TP values were 4.6 (2.3–6.7), 4.8 (3.5–8.8), and 6.8 (4.0–13.1) pmol//1 × 106 cells (Friedman P = 0.01). In mixed model analyses: ZDV-TP (fmol/1 × 106 cells) = 42–0.32 (CD4%); P < 0.001 and 3TC-TP (pmol/1 × 106 cells) = 7.3–0.03(CD4%); P = 0.003. In HIV-seronegative volunteers, 3TC-TP concentrations in PBMC reflected the concentrations within CD4 T cells, but ZDV-TP concentrations were more than 70% lower in CD4 T cells than in PBMC. Thus, TP concentrations differ according to cell type in vivo with corresponding efficacy and toxicity implications for cells with low or high triphosphates.Keywords
This publication has 20 references indexed in Scilit:
- Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.Journal of Antimicrobial Chemotherapy, 2006
- Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography–tandem mass spectroscopy; an indirect quantitation methodologyJournal of Chromatography B, 2006
- Less than the Sum of Its Parts: Failure of a Tenofovir‐Abacavir‐Lamivudine Triple‐Nucleoside RegimenThe Journal of Infectious Diseases, 2005
- Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV‐Infected Antiretroviral‐Naive SubjectsThe Journal of Infectious Diseases, 2005
- Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 InfectionNew England Journal of Medicine, 2004
- The Cellular Pharmacology of Nucleoside‐ and Nucleotide‐Analogue Reverse‐Transcriptase Inhibitors and Its Relationship to Clinical ToxicitiesClinical Infectious Diseases, 2004
- Equivalent Steady-State Pharmacokinetics of Lamivudine in Plasma and Lamivudine Triphosphate within Cells following Administration of Lamivudine at 300 Milligrams Once Daily and 150 Milligrams Twice DailyAntimicrobial Agents and Chemotherapy, 2004
- Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individualsAIDS, 2003
- Zidovudine phosphorylation in HIV-infected patients and seronegative volunteersAIDS, 1994
- Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.Journal of Clinical Investigation, 1993